SOS1-IN-28
SOS1-IN-28 is an orally active, blood-brain barrier permeable SOS1 inhibitor with an IC50 value of 0.11 μM. SOS1-IN-28 disrupts the SOS1: KRAS protein-protein interaction, with an IC50 of 0.29 μM for the KRAS-RAF interaction. SOS1-IN-28 blocks GTP loading of KRAS, inhibits RAS-MAPK pathway activity, and reduces cancer cell proliferation. SOS1-IN-28 can be used for the research of KRASG12C-mutant lung cancer.
For research use only. We do not sell to patients.
- Formula: C16H14F4N4O2
- Molecular Weight:370.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
SOS1 0.11 μM (IC50) |
SOS1-IN-28 (Compound 27) (0.03 nM-30 μM; 6 days) inhibits the proliferation of NCI-H358 SOS2-/- cell spheroids in a 3D assay with a GI50 of 0.33 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude male mice (Envigo)[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced deeper, more sustained suppression of DUSP6 mRNA and phosphorylated ERK (pERK) at 4 h, 8 h, and 16 h compared to KRASG12C inhibitor alone.
Reduced DUSP6 mRNA expression.
Reduced pERK protein levels statistically significantly relative to vehicle control at all three time points.
Maintained unbound plasma concentrations above its biochemical and cellular proliferation IC50 for up to 16 h.
Chemical Information
-
Molecular Weight 370.30
-
Formula C16H14F4N4O2
-
SMILES
FC1=C(C(F)(F)F)C=CC=C1[C@@H](C)NC(C2=CC=NC(C(NC)=O)=N2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)